EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country

Thomas Mooney, Elizabeth Smout, Bailah Leigh, Brian Greenwood, Luisa Enria, David Ishola, Daniela Manno, Mohamed Samai, Macaya Douoguih, Deborah Watson-Jones, Thomas Mooney, Elizabeth Smout, Bailah Leigh, Brian Greenwood, Luisa Enria, David Ishola, Daniela Manno, Mohamed Samai, Macaya Douoguih, Deborah Watson-Jones

Abstract

Background/aims During the 2014-2016 West African Ebola epidemic, clinical trials were fast-tracked in order to identify prophylactic vaccines and experimental treatments that might be useful in preventing or treating Ebola. These trials included the ongoing EBOVAC-Salone study, which was established and implemented in Sierra Leone to assess the safety and immunogenicity of the Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccine regimen. Methods This article describes the experiences of the EBOVAC-Salone research team in setting up and implementing the trial, and provides recommendations for research teams aiming to conduct clinical trials in future outbreak situations. Results Establishing a clinical trial during an outbreak brought some unique challenges, including those related to trial design and the regulatory environment, operational issues, and community engagement. The situation was further complicated by the weak infrastructure and limited experience of clinical trials in Sierra Leone. However, operating in an outbreak context also brought some benefits to the research team, including strong stakeholder support. The EBOVAC-Salone study recruited participants both during and after the outbreak, leading to additional challenges to trial implementation during the post-outbreak transition. Conclusion Many lessons have been learned about setting up and implementing a clinical trial during a devastating Ebola epidemic, and some of the experiences of the EBOVAC-Salone team were mirrored by those of other researchers operating in the region. Common to several of these research groups is a recommendation that research should be more closely incorporated into outbreak response planning, which could expedite the establishment of timely and appropriate research projects. We recommend that the lessons learned by researchers during the West African Ebola epidemic are built into programmes and strategies to improve the responses to future epidemics, wherever they occur.

Trial registration: ClinicalTrials.gov NCT02509494.

Keywords: Ebola; Sierra Leone; epidemic; lessons; recommendations; trial; vaccine.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. World Health Organization (WHO). Ebola situation report – 10 June 2016. Report, World Health Organization, Geneva, 2016,
    1. EBOVAC Projects. Developing a vaccine for Ebola, (2015, accessed 1 March 2017).
    1. Innovative Medicines Initiatives. Ebola+: Ebola and other filoviral haemorrhagic fevers, (2015, accessed 1 March 2017).
    1. EBOVAC Projects. EBODAC, (2015, accessed 28 March 2017).
    1. Widdowson M, Schrag SJ, Carter RJ, et al. Implementing an Ebola vaccine study – Sierra Leone. MMWR 2016; 65: 98–106.
    1. Thielman NM, Cunningham CK, Woods C, et al. Ebola clinical trials: five lessons learned and a way forward. Clin Trials 2016; 13: 83–86.
    1. Lang T. Ebola: embed research in outbreak response. Nature 2015; 524: 29–31.
    1. Larson GS, Baseler BR, Hoover ML, et al. Conventional wisdom versus actual outcomes: challenges in the conduct of an Ebola vaccine trial in Liberia during the international public health emergency. Am J Trop Med Hyg 2017; 97: 10–15.
    1. Beavogui AH, Delamou A, Yansane ML, et al. Clinical research during the Ebola virus disease outbreak in Guinea: lessons learned and ways forward. Clin Trials 2016; 13: 73–78.
    1. Tully CM, Lambe T, Gilbert SC, et al. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis 2015; 15: 356–359.
    1. Vandebosch A, Mogg R, Goeyvaerts N, et al. Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: statistical considerations, design rationale, and challenges. Clin Trials 2016; 13: 57–65.
    1. Akanmori B, Bellah A, Ward M, et al. The African Vaccine Regulatory Forum (AVAREF): a platform for collaboration in a public health emergency. WHO Drug Inform 2015; 29: 127–132.
    1. World Health Organization. Ethical considerations for use of unregistered interventions for Ebola virus disease: report of an advisory panel to WHO, (2014, accessed 1 March 2017).
    1. Emergency Ebola Anthropology Network. Advisory brief: culture and clinical trials, (2015, accessed 2 March 2017).
    1. World Health Organization. WHO Ebola R&D effort – vaccines, therapies, diagnostics, (2015, accessed 12 February 2018).
    1. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384: 1423–1424.
    1. Calain P. The Ebola clinical trials: a precedent for research ethics in disasters. J Med Ethics 2018; 44: 3–8.
    1. Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet 2014; 384: 1896–1899.
    1. Schuklenk U. Future infectious disease outbreaks: ethics of emergency access to unregistered medical Interventions and clinical trial designs. Dev World Bioeth 2016; 16: 2–3.
    1. Enria L, Lees S, Smout E, et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health 2016; 16: 1140.
    1. Gomes MF, de laFuente-Núñez V, Saxena A, et al. Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reprod Health 2017; 14: 172.
    1. Wilkinson A, Leach M. Briefing: Ebola – myths, realities, and structural violence. Afr Aff 2014; 114: 136–148.
    1. Evans DK, Goldstein M, Popova A. Health-care worker mortality and the legacy of the Ebola epidemic. Lancet Glob Health 2015; 3:e439–e440.
    1. World Health Organization. Global health observatory data repository, (2015, accessed 8 November 2016).
    1. United Nations Development Programme. Work for human development. Briefing note for countries on the 2015 human development report: Sierra Leone, (2015, accessed 2 March 2017).

Source: PubMed

3
Abonneren